A few nice Weight loss images I found:
Metamfetamin 5 mg
Image by ADHD CENTER
Metamfetamin kan brukas
Bipacksedel
Information till förskrivare
Diskutera här påFlickr om metamfetamin alltid behöver vara bra eller dåligt, eller om det finns mera nyanserade sätt att se på det hela.
Metamfetamin kan missbrukas och
–Metamfetamin kan missbrukas: se konsekvenserna
och missbruket ökar snabbt. Speciellt farligt för personer med ADHD då missbruk av metamfetamin reglerar ned densiteten på dopaminreceptorerna.
Metamfetamin – the faces of meth
Klassiker om vad som händer med metamfetaminmissbrukaren, åldrandet och tänderna. Blicken, huden och ödesränderna.
Meth större hjärna med mindre innehåll
Vad som händer i hjärnan hos Meth missbrukare, hjärnan växer på grund av att den svullnar och densiteten på dopaminreceptorerna regleras ned. Men också att metamfetamin rätt använt kan vara bra samt varför. Skillnaden mellan enantiomererna hur hur otroligt olika de verkar.
Metamfetamin & ADHD + Hel dokumentär
Hel dokumentärfilm från National Geographic om världens farligaste drog: Metamfetamin,
Den här dokumentären kanske om inte annat kan förklara lite av varför Metamfetamin fått det rykte som det har, vilka konsekvenserna av ett missbruk blir osv. Ãven om dokumentären inte alls förklarar att personer med ADHD löper en ökad risk att fastna i ett metamfetaminmissbruk och att det på sikt kommer att göra problemen mycket värre tack vare att höga doser reglerar ned antalet och densiteten på dopamin receptorerna. Så att det som frälser dig också kommer att döda dig har kanske aldrig varit sannare än här.
Metamfetamin de direkta & indirekta skadeverkningarna
-Se Oprahshow nedan om metamfetaminmissbruk
-ohämmad sex med främlingar och sambanden
Fler och fler rapporter kommer om metamfetamin eller crystal meth som en del föredrar att kalla det men skadeverkningarna av ett missbruk direkt säger kanske inte så mycket om de indirekta skadeverkningarna av missbruket, vilket varit väldigt vanligt och utbrett i vissa kretsar i bland annat New York.
Marknadsföringen av Meth amfetamin till gravida
Den Pengakåta pillerindustrin har genom åren haft en rad smaklösheter för sig förutom att dölja resultat som talar till sitt preparats nackdel så manipuleras och har det manipulerats en hel del igenom åren. En speciellt intressant grupp att kränga "de nya supervetenskapliga" produkterna till har varit kvinnor, ofta med någon skavank som medicinjättarna inte alls varit sena med att marknadsföra med vetenskap som täckmantel. Det kan vara den feta kvinnan, den okåta kvinnan, den otacksamma kvinnan eller bara kvinnan som inte hinner med att städa rent i hemmet. Eller varför inte suggan som blivit på smällen och fettnat till? Behöver inte hon lite metamfetamin?
så här farligt lever användarna
Metamfetamin utbrett i hela skåne
Produktbeskrivning på Engelska
METH
Teratogenic effects: Pregnancy Category C. Methamphetamine has been shown to have teratogenic and embryocidal effects in mammals given high multiples of the human dose. There are no adequate and well-controlled studies in pregnant women. METH tablets should
not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Nonteratogenic effects: Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation and significant lassitude.
Usage in Nursing Mothers: Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.
Pediatric Use: Safety and effectiveness for use as an anorectic agent in children below the age of 12 years have not been established. Long-term effects of methamphetamine in children have not been established (see WARNINGS). Drug treatment is not indicated in all cases of the behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability and impulsivity. It should be considered only in light of the complete history and evaluation of the child. The decision to prescribe METH tablets should depend on the physicianâs assessment of the chronicity and severity of the childâs symptoms and their appropriateness for his/her age. Prescription should not depend solely on the presence of one or more of the behavioral characteristics. When these symptoms are associated with acute stress reactions, treatment with METH tablets is usually not indicated. Clinical experience suggests that in psychotic children, administration of METH tablets may exacerbate symptoms of behavior disturbance and thought disorder. Amphetamines have been reported to exacerbate motor and phonic tics and Touretteâs syndrome. Therefore, clinical evaluation for tics and Touretteâs syndrome in children and their families should precede use of stimulant medications.
ADVERSE REACTIONS
The following are adverse reactions in decreasing order of severity within each category that have been reported: Cardiovascular: Elevation of blood pressure, tachycardia and palpitation. Fatal cardiorespiratory arrest has been reported, mostly in the context of abuse/misuse. Central Nervous System: Psychotic episodes have been rarely
eported at recommended doses. Dizziness, dysphoria, overstimulation, euphoria, insomnia, tremor, restlessness and headache. Exacerbation of motor and phonic tics and Touretteâs syndrome. Gastrointestinal: Diarrhea, constipation, dryness of mouth, unpleasant taste and other gastrointestinal disturbances.
Hypersensitivity: Urticaria.
Endocrine: Impotence and changes in libido.
Miscellaneous: Suppression of growth has been reported with the
long-term use of stimulants in children (see WARNINGS).
DRUG ABUSE AND DEPENDENCE
Controlled Substance: METH tablets are subject to control under
DEA schedule II.
Abuse: Methamphetamine has been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with methamphetamine include
severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis often clinically indistinguishable from schizophrenia. Abuse and/or misuse of methamphetamine have resulted in death. Fatal cardiorespiratory arrest has been reported in the context of abuse and/or misuse of methamphetamine.
OVERDOSAGE depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. Emergence of New Psychotic or Manic Symptoms: Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of
treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlledstudies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.
Aggression: Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility. There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued. Visual Disturbance Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.
PRECAUTIONS
General: METH tablets should be used with caution in patients with even mild hypertension. Methamphetamine should not be used to combat fatigue or to replace rest in normal persons. Prescribing and dispensing of methamphetamine should be limited to the smallest amount that is feasible at one time in order to minimize the possibility of overdosage. Information for Patients: The patient should be informed that methamphetamine may impair the ability to engage in potentially hazardous activities, such as, operating machinery or driving a motor vehicle.
The patient should be cautioned not to increase dosage, except on advice of the physician. Prescribers or other health professionals should inform patients, their families and their caregivers about the benefits and risks associated with treatment with methamphetamine and should counsel them it its appropriate use. A patient Medication Guide is available for METH. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.
Drug Interactions: Insulin requirements in diabetes mellitus may be altered in association with the use of methamphetamine and the concomitant dietary regimen. Methamphetamine may decrease the hypotensive effect of guanethidine. METH should not be used concurrently with monoamine oxidase inhibitors (see CONTRAINDICATIONS). Concurrent administration of tricyclic antidepressants and indirect- acting sympathomimetic amines such as the amphetamines, should be closely supervised and dosage carefully adjusted. Phenothiazines are reported in the literature to antagonize the CNS stimulant action of the amphetamines.
INDICATIONS AND USAGE
Attention Deficit Disorder with Hyperactivity: METH tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. Exogenous Obesity: as a short-term (i.e., a few weeks) adjunct in a regimen of weight reduction based on caloric restriction, for patients in whom obesity is refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of METH tablets (see CLINICAL PHARMACOLOGY) should be weighed against possible risks inherent in use of the drug, such as those described below.
CONTRAINDICATIONS
METH tablets are contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors; hypertensive crisis may result. It is also contraindicated in patients with glaucoma, advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism or known hypersensitivity or idiosyncrasy to sympathomimetic amines. Methamphetamine should not be given to patients who are in an agitated state or who have a history of drug abuse.
WARNINGS
Tolerance to the anorectic effect usually develops within a few weeks. When this occurs, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued (see DRUG ABUSE AND DEPENDENCE).
Serious Cardiovascular Events
Sudden Death and Pre existing Structural Cardiac Abnormalities
or Other Serious Heart Problems:
Children and Adolescents: Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a
stimulant drug.
Adults: Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs. Hypertension and other Cardiovascular Conditions: Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia. Assessing Cardiovascular Status in Patients being Treated with Stimulant Medications: Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.
Psychiatric Adverse Events
Pre-existing Psychosis:
Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Bipolar Illness: Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in suchpatients. Prior to initiating treatment with a stimulant,
METH®
Methamphetamine
Hydrochloride
Tablets, USP only
DESCRIPTION
METH® (methamphetamine hydrochloride tablets, USP), chemically known as (S)-N,α-dimethylbenzeneethanamine hydrochloride, is a member of the amphetamine group of sympathomimetic amines. It has the following structural formula:
CLINICAL PHARMACOLOGY
Methamphetamine is a sympathomimetic amine with CNS stimulant activity. Peripheral actions include elevation of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. Drugs of this class used in obesity are commonly known as âanorecticsâ or âanorexigenicsâ. It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions, or metabolic effects, may be involved, for example. Adult obese subjects instructed in dietary management and treated with âanorecticâ drugs, lose more weight on the average than those treated with placebo and diet, as determined in relatively short-term clinical trials.
The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The origins of the increased weight loss due to the various possible drug effects are not established. The amount of weight loss associated with the use of an âanorecticâ drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician-investigator, the population treated, and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.
The natural history of obesity is measured in years, whereas the studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited. The mechanism of action involved in producing the beneficial behavioral changes seen in hyperkinetic children receiving methamphetamine is unknown. In humans, methamphetamine is rapidly absorbed from the gastrointestinal tract. The primary site of metabolism is in the liver by aromatic hydroxylation, N-dealkylation and deamination. At least seven metabolites have been identified in the urine. The biological half-life has been reported in the range of 4 to 5 hours. Excretion occurs primarily in the urine and is dependent on urine pH. Alkaline urine will significantly increase the drug half-life. Approximately 62% of an oral dose is eliminated in the urine within the first 24 hours with about one-third as intact drug and the remainder as metabolites.
METHAMPHETAMINE HAS A HIGH POTENTIAL FOR
ABUSE. IT SHOULD THUS BE TRIED ONLY IN
CLINICAL PHARMACOLOGY. HAVE A NICE DAY.
Bara metylfenidat rekommenderas av de europeiska kontrollmyndigheterna för behandling av ADHD
Grand Opening of Oceanview Medical Weight Loss Spa in Frisco, TX
Image by Oceanview Med Spa
This is licensed under Attribution-ShareAlike Creative Commons. You are free to use this photo – please give attribution to Oceanview Medical Weight Loss Spa of Frisco, TX and link back to www.oceanviewweightlossmedical.com
National Zoo Mourns Loss of Przewalski’s Horse
Image by Smithsonian’s National Zoo
Photo Credit: Mehgan Murphy, Smithsonian’s National Zoo
The Smithsonian’s National Zoo is mourning the death of its 23-year-old Przewalski’s horse, a male named Rolles, who was humanely euthanized this morning. A final pathology report will provide more information.
In July, keepers observed that Rolles had some nasal discharge. Zoo veterinarians prescribed oral antibiotics, which helped initially. About 10 days later, he developed a visible mass on the side of his nose. Rolles also lost weight and rubbed the affected area, an indication that the mass caused him discomfort.
Zoo veterinarians, in consultation with an outside equine veterinarian, performed a full examination on Rolles, including X-rays and nasal endoscopy. The location of the tumor greatly limited the options for treatment. Animal care staff elected to humanely euthanize Rolles based on his poor long-term prognosis.
Born at the Bronx Zoo June 10, 1990, Rolles arrived at the National Zoo in 2008. Most zoo animals participate in a breeding program called the Species Survival Plan. The SSP scientists determine which animals to breed by considering their genetic makeup, nutritional and social needs, temperament and overall health. Rather than breed, Rolles served as a non-breeding companion for Rose Marie, the Zoo’s 27-year-old female Przewalski’s horse. He also acted as an educational ambassador for his species, illustrating the social nature and behavior of Przewalski’s horses to scientists, keepers and Zoo visitors.
This species is considered endangered by the International Union for Conservation of Nature’s Red List of Threatened Species. Scientists at the Zoo’s Smithsonian Conservation Biology Institute recently celebrated a huge breakthrough for the survival of this species with the birth of a female Przewalski’s horse—the first born via artificial insemination. Visitors can see Rose Marie on exhibit adjacent to the Small Mammal House.
# # #
